Cargando…

Adoption of PCSK9 Inhibitors Among Patients With Atherosclerotic Disease

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors represent a promising class of lipid‐lowering therapy, although their use has been limited by cost concerns. METHODS AND RESULTS: A retrospective cohort study was conducted using a nationwide commercial claims database comp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dayoub, Elias J., Eberly, Lauren A., Nathan, Ashwin S., Khatana, Sameed Ahmed M., Adusumalli, Srinath, Navar, Ann Marie, Giri, Jay, Groeneveld, Peter W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8200752/ https://www.ncbi.nlm.nih.gov/pubmed/33904340 http://dx.doi.org/10.1161/JAHA.120.019331

Ejemplares similares

Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US
por: Eberly, Lauren A., et al.
Publicado: (2021)

Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US
por: Eberly, Lauren A., et al.
Publicado: (2021)

Predictors of telemedicine use during the COVID-19 pandemic in the United States–an analysis of a national electronic medical record database
por: Khatana, Sameed Ahmed M., et al.
Publicado: (2022)

Association Between Community‐Level Violent Crime and Cardiovascular Mortality in Chicago: A Longitudinal Analysis
por: Eberly, Lauren A., et al.
Publicado: (2022)

Federal Payments for Coronary Revascularization Procedures Among Dual Enrollees in Medicare Advantage and the Veterans Affairs Health Care System
por: Dayoub, Elias J., et al.
Publicado: (2020)

Racial, Ethnic, and Socioeconomic Inequities in Access to Left Atrial Appendage Occlusion
por: Reddy, Kriyana P., et al.
Publicado: (2023)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Health Disparities and the Coronavirus Disease 2019 (COVID-19) Pandemic in the USA
por: Khatana, Sameed Ahmed M., et al.
Publicado: (2020)

Telemedicine and the Forgotten America
por: Julien, Howard M., et al.
Publicado: (2020)

Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans
por: Derington, Catherine G., et al.
Publicado: (2021)

Association of Extreme Heat With All-Cause Mortality in the Contiguous US, 2008-2017
por: Khatana, Sameed Ahmed M., et al.
Publicado: (2022)

Trends in PCSK9 Inhibitor Prescriptions before and after the Price Reduction in Patients with Atherosclerotic Cardiovascular Disease
por: Smith, Alex, et al.
Publicado: (2021)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Cardiovascular Disease Burden and Outcomes Among American Indian and Alaska Native Medicare Beneficiaries
por: Eberly, Lauren A., et al.
Publicado: (2023)

Geographic and Socioeconomic Disparities in Major Lower Extremity Amputation Rates in Metropolitan Areas
por: Fanaroff, Alexander C., et al.
Publicado: (2021)

Effect of PCSK9 on atherosclerotic cardiovascular diseases and its mechanisms: Focus on immune regulation
por: Ma, Minglu, et al.
Publicado: (2023)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
por: Toscano, Arianna, et al.
Publicado: (2022)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods
por: Basiak, Marcin, et al.
Publicado: (2023)

Efficacy and Safety of PCSK9 Inhibitors in Hypercholesterolemia Associated With Refractory Nephrotic Syndrome
por: Jatem, Elias, et al.
Publicado: (2020)

Real world effectiveness of PCSK-9 inhibitors combined with statins versus statins-based therapy among patients with very high risk of atherosclerotic cardiovascular disease in China (RWE-PCSK study)
por: LIU, Yu-Qi, et al.
Publicado: (2021)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Statement for Appropriate Clinical Use of PCSK9 Inhibitors
por: Nohara, Atsushi, et al.
Publicado: (2018)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Finding inhibitors for PCSK9 using computational methods
por: Zainab, Rida, et al.
Publicado: (2021)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Investigation of highly expressed PCSK9 in atherosclerotic plaques and ox-LDL-induced endothelial cell apoptosis
por: Li, Jiao, et al.
Publicado: (2017)

PCSK9 is minimally associated with HDL but impairs the anti-atherosclerotic HDL effects on endothelial cell activation
por: Dafnis, Ioannis, et al.
Publicado: (2022)

The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID‐19
por: Selvaraj, Senthil, et al.
Publicado: (2020)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

PCSK9 Inhibitors: What Lies Beyond Monoclonal Antibodies?
por: EBioMedicine
Publicado: (2015)

Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor
por: Kasichayanula, Sreeneeranj, et al.
Publicado: (2018)

PCSK9 inhibitors: Add-on therapy to reduce stroke risk
por: Earl, Grace
Publicado: (2019)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_8vurnjktudicrvdiq8a8urnjqj